Gilead Sciences stock gains 0.73% premarket to EUR 153.92
Published on 11/12/2026 at 08:14 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSHIV Prevention Data Support Pipeline Focus
- Twice-yearly lenacapavir showed higher one-year PrEP persistence than daily oral F/TDF in the PURPOSE 5 study.
- Gilead reported zero HIV acquisitions among participants receiving lenacapavir during the 52-week study period.
- The findings strengthen the focus on long-acting HIV prevention as Gilead presents data at HIV Glasgow.
Gilead Sciences stock traded at EUR 153.92 on Lang & Schwarz at 08:12 CET on Thursday, November 12, 2026, 0.73 percent above the Xetra close of Wednesday, November 11, 2026.
Long-Acting HIV Prevention Gains Focus
Recent PURPOSE 5 findings are keeping Gilead's long-acting HIV prevention strategy in focus. In a November 6 release, Gilead Sciences said 85.6 percent of participants receiving twice-yearly lenacapavir remained persistent on PrEP through Week 52, compared with 46.3 percent for daily oral emtricitabine/tenofovir disoproxil fumarate.
The company said the difference was statistically significant and that no HIV acquisitions occurred among participants receiving lenacapavir during the 52-week study period. The Phase 2 PURPOSE 5 study is evaluating PrEP persistence among people in the United Kingdom and France who were not taking PrEP when they joined the trial.
The findings were scheduled for presentation at HIV Glasgow 2026. For investors, the data add a pipeline catalyst to Gilead's HIV franchise, while the twice-yearly dosing schedule addresses the adherence challenge associated with daily prevention pills.
The wider U.S. market context is covered in the S&P 500.
